The company have informed us that they are no longer seeking regulatory approval in this indication. Therefore the appraisal is suspended.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 821

Email enquiries

Stakeholders

Companies sponsors Chugai Pharma (anamorelin)
  Helsinn (anamorelin)
Others Department of Health
  NHS England
  NHS Ipswich and East Suffolk CCG
  NHS Southwark CCG
  Welsh Government
Patient carer groups Black Health Agency
  British Lung Foundation
  Cancer Black Care
  Cancer Equality
  HAWC
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Muslim Council of Britain
  Roy Castle Lung Cancer Foundation
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
  UK Lung Cancer Coalition
Professional groups Association of Cancer Physicians
  Association of Respiratory Nurse Specialists
  British Dietetic Association
  British Geriatrics Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Thoracic Oncology Group
  British Thoracic Society
  Cancer Research UK
  National Lung Cancer Forum for Nurses
  Primary Care Respiratory Society UK
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Health Forum
  UK Oncology Nursing Society
Associated public health groups Public Health England
  Public Health Wales
General commentators Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Commercial Medicines Unit
  NHS Confederation
  Scottish Medicines Consortium
Relevant research groups Cochrane Lung Cancer Group
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
18 August 2022 Discontinued. The company have informed us that they are no longer seeking regulatory approval in this indication. Therefore the appraisal is suspended.
21 June 2017 This appraisal has now been suspended and the appraisal committee discussion that was due to take place has been cancelled. This is due to an update on the regulatory status as the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, “recommending the refusal of the marketing authorisation for the medicinal product anamorelin intended for the treatment of anorexia, cachexia or unintended weight loss in patients with non-small cell lung cancer”.
08 December 2016 Invitation to participate
08 June 2016 Referral

For further information on our processes and methods, please see our CHTE processes and methods manual